Home Tools
Log in
Cart

EGFR

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands.
Signaling Pathways | Target | TargetMol
Cat. No. Product name CAS No. Purity Chemical Structure
T12372 PAT-505 1782070-22-7 98.84%
PAT-505
PAT-505 is an orally available, selective and potent inhibitor of autologous epidermal growth factor (IC50 2 nM in Hep3B cells, 9.7 nM in human blood, 62 nM in m...
T2610 BMS-599626 714971-09-2 98.79%
BMS-599626
BMS-599626 (AC480) has been used in trials studying the treatment of Cancer, Metastases, and HER2 or EGFR Expressing Advanced Solid Malignancies.
T2460 JAK 3 inhibitor IV 58753-54-1 98%
JAK 3 inhibitor IV
JAK 3 inhibitor IV (ZM 39923 hydrochloride) is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be...
T9923 Nimotuzumab 828933-51-3 95.00%
Nimotuzumab
Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
T16265 Naluzotan 740873-06-7 100%
Naluzotan
Naluzotan(PRX 00023) is a novel and potent 5-HT1A agonist with IC50 and Ki values of approximately 20 nM and 5.1 nM, respectively.Naluzotan is a potent hERG K+ c...
T12175 Naquotinib mesylate 1448237-05-5
Naquotinib mesylate
Naquotinib mesylate (ASP8273 (mesylate)) is an orally available, mutant-selective and irreversible inhibitor of EGFR(iC50s of 8-33 nM and 230 nM for toward EGFR ...
T3P2855 Chamigrenal 19912-84-6
Chamigrenal
β-Chamigrenal has anti-inflammatory activity, it has inhibitory effects on lipopolysaccharide-induced nitric oxide and prostaglandin E2 production in RAW 264.7 m...
T13559 Astragaloside VI 84687-45-6 98%
Astragaloside VI
Astragaloside VI could improve wound healing by activating the EGFR/ERK signaling pathway.
T14677 BMS-690514 859853-30-8 98%
BMS-690514
BMS-690514 is a potent and orally active inhibitor of EGFR and VEGFR. It has IC50s of 5, 20 and 60 nM for EGFR, HER 2 and HER 4, respectively.
TN3042 4-Hydroxycinnamamide 194940-15-3 98%
4-Hydroxycinnamamide
4-Hydroxycinnamamide has antioxidant activity. 4-Hydroxycinnamamide derivatives are specific inhibitors of tyrosine-specific protein kinases.
T11164 EGFR mutant-IN-1 98%
EGFR mutant-IN-1
EGFR mutant- in-1, A 5-methylpyrimidopyridone derivative are effective selective EGFRL858R/T790M/C797S mutant inhibitors with IC50 of 27.5 nM, which significantl...
T78326 Depatuxizumab 1471999-69-5 98%
Depatuxizumab
Depatuxizumab, a brain-penetrant, humanized anti-EGFR monoclonal antibody, selectively inhibits the growth of mutant EGFRvIII and wild-type EGFR xenograft models...
T78335 Inetetamab 98%
Inetetamab
Inetetamab, a monoclonal antibody, targets domain IV of the HER2 receptor and demonstrates antitumor activities both as a standalone therapy and when combined wi...
T78574 EGFR-IN-85 1956378-29-2 98%
EGFR-IN-85
EGFR-IN-85 (Compound 1), an EGFR inhibitor, exhibits potent activity with an IC50 of 0.19 μM against EGFRvⅢ phosphorylation and can suppress intratumoral EGFR si...
T78634 2′-Thioadenosine 136904-69-3 98%
2′-Thioadenosine
2'-Thioadenosine (PD157432) serves as a selective and irreversible inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, demonstrating an IC50 value of 45 µM against ...
T78788 EGFR-IN-82 2568086-81-5 98%
EGFR-IN-82
EGFR-IN-82 (Compound 8a) is a potent, orally active inhibitor of EGFR, exhibiting IC50 values of 0.09 nM for EGFR L858R/T790M/C797S and 0.06 nM for EGFR Del19/T7...
T78849 EGFR/BRAFV600E-IN-2 98%
EGFR/BRAFV600E-IN-2
E07 Aptamer, targeting the human epidermal growth factor receptor (hEGFR), competes with epidermal growth factor (EGF) for binding to a unique epitope on EGFR. T...
T78850 EGFR/BRAFV600E-IN-3 98%
EGFR/BRAFV600E-IN-3
EGFR/BRAFV600E-IN-3 is an inhibitor targeting EGFR, BRAFV600E, and EGFRT790M with IC50 values of 57 nM, 68 nM, and 9.70 nM, respectively. It induces apoptosis an...
T78862 EGFR-IN-86 98%
EGFR-IN-86
EGFR-IN-86 (compound 4i), an EGFR inhibitor (IC50: 1.5 nM), demonstrates potent activity against glioblastoma by inducing apoptosis and causing G2/M phase cell c...
T78877 MTX-241F 98%
MTX-241F
MTX-241F, a selective small molecule inhibitor, targets members of the EGFR and PI3 kinase families. It penetrates the blood-brain barrier, providing long-term t...
PAT-505
T12372
PAT-505 is an orally available, selective and potent inhibitor of autologous epidermal growth factor (IC50 2 nM in Hep3B cells, 9.7 nM in human blood, 62 nM in m...
BMS-599626
T2610
BMS-599626 (AC480) has been used in trials studying the treatment of Cancer, Metastases, and HER2 or EGFR Expressing Advanced Solid Malignancies.
JAK 3 inhibitor IV
T2460
JAK 3 inhibitor IV (ZM 39923 hydrochloride) is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be...
Nimotuzumab
T9923
Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
Naluzotan
T16265
Naluzotan(PRX 00023) is a novel and potent 5-HT1A agonist with IC50 and Ki values of approximately 20 nM and 5.1 nM, respectively.Naluzotan is a potent hERG K+ c...
Naquotinib mesylate
T12175
Naquotinib mesylate (ASP8273 (mesylate)) is an orally available, mutant-selective and irreversible inhibitor of EGFR(iC50s of 8-33 nM and 230 nM for toward EGFR ...
Chamigrenal
T3P2855
β-Chamigrenal has anti-inflammatory activity, it has inhibitory effects on lipopolysaccharide-induced nitric oxide and prostaglandin E2 production in RAW 264.7 m...
Astragaloside VI
T13559
Astragaloside VI could improve wound healing by activating the EGFR/ERK signaling pathway.
BMS-690514
T14677
BMS-690514 is a potent and orally active inhibitor of EGFR and VEGFR. It has IC50s of 5, 20 and 60 nM for EGFR, HER 2 and HER 4, respectively.
4-Hydroxycinnamamide
TN3042
4-Hydroxycinnamamide has antioxidant activity. 4-Hydroxycinnamamide derivatives are specific inhibitors of tyrosine-specific protein kinases.
EGFR mutant-IN-1
T11164
EGFR mutant- in-1, A 5-methylpyrimidopyridone derivative are effective selective EGFRL858R/T790M/C797S mutant inhibitors with IC50 of 27.5 nM, which significantl...
Depatuxizumab
T78326
Depatuxizumab, a brain-penetrant, humanized anti-EGFR monoclonal antibody, selectively inhibits the growth of mutant EGFRvIII and wild-type EGFR xenograft models...
Inetetamab
T78335
Inetetamab, a monoclonal antibody, targets domain IV of the HER2 receptor and demonstrates antitumor activities both as a standalone therapy and when combined wi...
EGFR-IN-85
T78574
EGFR-IN-85 (Compound 1), an EGFR inhibitor, exhibits potent activity with an IC50 of 0.19 μM against EGFRvⅢ phosphorylation and can suppress intratumoral EGFR si...
2′-Thioadenosine
T78634
2'-Thioadenosine (PD157432) serves as a selective and irreversible inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, demonstrating an IC50 value of 45 µM against ...
EGFR-IN-82
T78788
EGFR-IN-82 (Compound 8a) is a potent, orally active inhibitor of EGFR, exhibiting IC50 values of 0.09 nM for EGFR L858R/T790M/C797S and 0.06 nM for EGFR Del19/T7...
EGFR/BRAFV600E-IN-2
T78849
E07 Aptamer, targeting the human epidermal growth factor receptor (hEGFR), competes with epidermal growth factor (EGF) for binding to a unique epitope on EGFR. T...
EGFR/BRAFV600E-IN-3
T78850
EGFR/BRAFV600E-IN-3 is an inhibitor targeting EGFR, BRAFV600E, and EGFRT790M with IC50 values of 57 nM, 68 nM, and 9.70 nM, respectively. It induces apoptosis an...
EGFR-IN-86
T78862
EGFR-IN-86 (compound 4i), an EGFR inhibitor (IC50: 1.5 nM), demonstrates potent activity against glioblastoma by inducing apoptosis and causing G2/M phase cell c...
MTX-241F
T78877
MTX-241F, a selective small molecule inhibitor, targets members of the EGFR and PI3 kinase families. It penetrates the blood-brain barrier, providing long-term t...
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
TargetMol